31.73 USD
▲+1.94+6.51%
盘后 32.00 +0.85%
2026-11-19
市值
$1.36B
市盈率
—
EPS
-1.31
股息率
—
52 周区间
16.50 – 50.81
成交量
1.90M
Beta
1.64
目标价
60.71
52W 低 16.5052W 高 50.81
价格走势
公司简介
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal...